Correlation between serum NRG-1 and MMP-9 levels and cognitive function of patients with stable schizophrenia

doi:10.3969/j.issn.1673-8640.2025.11.010

Abstract

Abstract:

Objective To investigate the correlation between serum neuregulin-1（NRG-1） and matrix metalloproteinase-9（MMP-9）levels and the cognitive function of patients with stable schizophrenia. Methods A total of 104 patients with stable schizophrenia（case group）and 70 healthy subjects（healthy control group）were enrolled from Tongji University Affiliated Mental Health Center from October 2023 to September 2024. The serum NRG-1 and MMP-9 levels were determined，and their cognitive functions were evaluated. Pearson correlation analysis was used to assess the correlation between serum NRG-1，MMP-9 levels and cognitive function. Logistic regression analysis was used to evaluate the influencing factors of cognitive dysfunction. Receiver operating characteristic（ROC）curve was used to evaluate the efficacy of NRG-1 and MMP-9 in determining the occurrence of cognitive dysfunction. Results Compared with healthy control group，the cognitive function of case group was lower（P<0.001），and the serum NRG-1 level was decreased（P<0.001），while the MMP-9 level was increased（P<0.001）. The cognitive function of healthy control group was not correlated with NRG-1 and MMP-9（P>0.05）. The cognitive function of case group [total score of repeatable battery for the assessment of neuropsychological status（RBANS）scale，immediate memory，verbal function，visual span，attention，delayed memory] was positively correlated with NRG-1（r values were 0.946，0.878，0.853，0.811，0.842 and 0.717，P<0.05）and negatively correlated with MMP-9（r values =-0.339，-0.372，-0.355，-0.072，-0.280 and -0.372，P<0.05）. Decreased NRG-1 level and increased MMP-9 level were risk factors for the occurrence of stable schizophrenia（P<0.001）. The areas under curves（AUC）of NRG-1，MMP-9 single and combined determinations for judging cognitive dysfunction were 0.787，0.723 and 0.858，respectively. Conclusions The serum NRG-1 and MMP-9 levels of patients with stable schizophrenia are related to cognitive function，and they have certain value in predicting cognitive dysfunction.

Key words: Neuregulin-1, Matrix metalloproteinase-9, Schizophrenia, Cognitive function

CLC Number:

R446.1

CHEN Qiuying, ZHANG Lei, ZHOU Shupei, YAO Miaomiao, WANG Lirong, YIN Haibo, LI Xin. Correlation between serum NRG-1 and MMP-9 levels and cognitive function of patients with stable schizophrenia[J]. Laboratory Medicine, 2025, 40(11): 1091-1096.

Figures/Tables 5

References 23

[1]	SOLMI M, SEITIDIS G, MAVRIDIS D, et al. Incidence,prevalence,and global burden of schizophrenia-data,with critical appraisal,from the Global Burden of Disease (GBD)2019[J]. Mol Psychiatry,2023,28(12):5319-5327.
[2]	王雪, 周郁秋, 刘东玮, 等. 精神分裂症不同时期认知功能损害特点及干预方式的研究进展[J]. 中国全科医学, 2021, 24(32):4121-4125.
[3]	温红霞, 史战明, 谭小林, 等. 精神分裂症认知功能影响因素研究进展[J]. 国际精神病学杂志, 2020, 47(3):454-456.
[4]	LI L, SHANG L, KANG W, et al. Neuregulin-1 promotes the proliferation,migration,and angiogenesis of human periodontal ligament stem cells in vitro[J]. Cell Biol Int, 2022, 46(5):792-805. DOI URL
[5]	SHAHRIARY G M, KATARIA H, KARIMI-ABDOLREZAEE S. Neuregulin-1 fosters supportive interactions between microglia and neural stem/progenitor cells[J]. Stem Cells Int, 2019,2019:8397158.
[6]	SALVANY S, CASANOVAS A, TARABAL O, et al. Localization and dynamic changes of neuregulin-1 at C-type synaptic boutons in association with motor neuron injury and repair[J]. FASEB J, 2019, 33(7):7833-7851. DOI PMID
[7]	MA Y, FAN P, ZHAO R, et al. Neuregulin-1 regulates the conversion of M1/M2 microglia phenotype via ErbB4-dependent inhibition of the NF-κB pathway[J]. Mol Biol Rep, 2022, 49(5):3975-3986. DOI
[8]	贾婷婷, 张程程. 整合全基因组关联研究和大脑表达数量性状位点探究精神分裂症重要风险基因[J]. 中华精神科杂志, 2022, 55(5):399-407.
[9]	WANG X, ZHANG F, MA W, et al. Increased levels of serum neuregulin 1 associated with cognitive impairment in vascular dementia[J]. Biomed Res Int, 2020,2020:6683747.
[10]	赵敏敏, 李小梅, 车坤, 等. 基质金属蛋白酶9与神经系统疾病发展研究进展[J]. 长治医学院学报, 2024, 38(5):398-402.
[11]	ARABSKA J, MARGULSKA A, STRZELECKI D, et al. Does metabolic status affect serum levels of BDNF and MMP-9 in patients with schizophrenia?[J]. Nord J Psychiatry, 2019, 73(8):515-521. DOI URL
[12]	SCHORETSANITIS G, DE FILIPPIS R, NTOGKA M, et al. Matrix metalloproteinase 9 blood alterations in patients with schizophrenia spectrum disorders:a systematic review and meta-analysis[J]. Schizophr Bull, 2021, 47(4):986-996. DOI URL
[13]	ZHENG W, JIANG W L, ZHANG X, et al. Use of the RBANS to evaluate cognition in patients with schizophrenia and metabolic syndrome:a meta-analysis of case-control studies[J]. Psychiatr Q, 2022, 93(1):137-149. DOI
[14]	段浠婷, 刘春宇, 赵晶晶. 精神分裂症认知功能障碍综述[J]. 国际精神病学杂志, 2018, 45(3):388-391.
[15]	GEBREEGZIABHERE Y, HABATMU K, MIHRETU A, et al. Cognitive impairment in people with schizophrenia:an umbrella review[J]. Eur Arch Psychiatry Clin Neurosci, 2022, 272(7):1139-1155. DOI
[16]	PETERSON A R, GARCIA T A, FORD B D, et al. Regulation of NRG-1-ErbB4 signaling and neuroprotection by exogenous neuregulin-1 in a mouse model of epilepsy[J]. Neurobiol Dis, 2021,161:105545.
[17]	陈彦霖, 陈诚, 李泽平, 等. NRG1/ErbB4信号通路与精神疾病关联的研究进展[J]. 中国现代医学杂志, 2020, 30(15):44-49.
[18]	ROBINSON H L, TAN Z, SANTIAGO-MARRERO I, et al. Neuregulin 1 and ErbB4 kinase actively regulate sharp wave ripples in the hippocampus[J]. J Neurosci, 2022, 42(3):390-404. DOI URL
[19]	TAN Z, ROBINSON H L, YIN D M, et al. Dynamic ErbB4 activity in hippocampal-prefrontal synchrony and top-down attention in rodents[J]. Neuron, 2018, 98(2):380-393. DOI PMID
[20]	HUANG L, TIAN W, CHEN X, et al. Peripheral neutrophils-derived matrix metallopeptidase-9 induces postoperative cognitive dysfunction in aged mice[J]. Front Aging Neurosci, 2022,14:683295.
[21]	KESHRI N, NANDEESHA H, RAJAPPA M, et al. Matrix metalloproteinase-9 increases the risk of cognitive impairment in schizophrenia[J]. Nord J Psychiatry, 2021, 75(2):130-134. DOI URL
[22]	SEITZ-HOLLAND J, ALEMÁN-GÓMEZ Y, CHO KIK, et al. Matrix metalloproteinase 9（MMP-9）activity, hippocampal extracellular free water,and cognitive deficits are associated with each other in early phase psychosis[J]. Neuropsychopharmacology, 2024, 49(7):1140-1150.
[23]	YANG H, H，ZHANG C, YANG M, et al. Variations of plasma oxidative stress levels in male patients with chronic schizophrenia. Correlations with psychopathology and matrix metalloproteinase-9: a case-control study[J]. BMC Psychiatry, 2024,(1):20.

组别	例数	NRG-1/（ng·mL^-1）	MMP-9/（ng·mL^-1）	RBANS量表总分/分	即刻记忆/分	视觉广度/分	言语功能/分	注意力/分	延时记忆/分
病例组	104	5.22±1.13	540.13±157.31	358.12±89.45	46.69±12.83	60.89±10.37	58.50±10.49	70.68±9.93	53.71±10.82
正常对照组	70	8.72±2.09	454.29±70.78	442.94±83.78	71.84±8.88	84.41±9.44	85.66±8.90	94.24±8.48	78.56±5.98
t值		12.80	4.88	24.01	15.28	15.20	18.36	16.27	19.43
P值		<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001

组别	例数	NRG-1/（ng·mL^-1）	MMP-9/（ng·mL^-1）	RBANS量表总分/分	即刻记忆/分	视觉广度/分	言语功能/分	注意力/分	延时记忆/分
病例组	104	5.22±1.13	540.13±157.31	358.12±89.45	46.69±12.83	60.89±10.37	58.50±10.49	70.68±9.93	53.71±10.82
正常对照组	70	8.72±2.09	454.29±70.78	442.94±83.78	71.84±8.88	84.41±9.44	85.66±8.90	94.24±8.48	78.56±5.98
t值		12.80	4.88	24.01	15.28	15.20	18.36	16.27	19.43
P值		<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001

组别	例数	性别		年龄/岁	受教育时间/年	发病年龄/岁	病程/年	氯丙嗪剂量/mg	PANSS总分/分
组别	例数	男/例	女/例	年龄/岁	受教育时间/年	发病年龄/岁	病程/年	氯丙嗪剂量/mg	PANSS总分/分
认知正常组	42	23	19	45.51±7.58	8.55±3.12	26（15，37）	12（6，18）	575.23±178.74	56.47±13.28
认知障碍组	62	47	15	47.69±5.73	8.27±1.98	28（17，40）	13（5，20）	612.43±202.64	57.55±10.22
统计值		5.040		0.576	0.617	0.294	0.073	0.517	1.734
P值		0.025		0.565	0.538	0.787	0.942	0.612	0.086
组别		PANSS阳性症状评分/分		PANSS阴性症状评分/分	PANS一般精神病理评分/分	抗乙酰胆碱药物使用情况		NRG-1/ （ng·mL^-1）	MMP-9/ （ng·mL^-1）
组别		PANSS阳性症状评分/分		PANSS阴性症状评分/分	PANS一般精神病理评分/分	是/例	否/例	NRG-1/ （ng·mL^-1）	MMP-9/ （ng·mL^-1）
认知正常组		12.42±5.66		22.43±7.30	27.83±7.42	22	20	5.86±0.88	470.79±157.15
认知障碍组		14.65±6.14		20.86±6.40	28.46±7.37	45	17	4.80±0.65	587.10±137.88
统计值		1.332		1.511	0.926	4.457		7.062	3.990
P值		0.190		0.134	0.357	0.035		<0.001	<0.001

组别	例数	性别		年龄/岁	受教育时间/年	发病年龄/岁	病程/年	氯丙嗪剂量/mg	PANSS总分/分
组别	例数	男/例	女/例	年龄/岁	受教育时间/年	发病年龄/岁	病程/年	氯丙嗪剂量/mg	PANSS总分/分
认知正常组	42	23	19	45.51±7.58	8.55±3.12	26（15，37）	12（6，18）	575.23±178.74	56.47±13.28
认知障碍组	62	47	15	47.69±5.73	8.27±1.98	28（17，40）	13（5，20）	612.43±202.64	57.55±10.22
统计值		5.040		0.576	0.617	0.294	0.073	0.517	1.734
P值		0.025		0.565	0.538	0.787	0.942	0.612	0.086
组别		PANSS阳性症状评分/分		PANSS阴性症状评分/分	PANS一般精神病理评分/分	抗乙酰胆碱药物使用情况		NRG-1/ （ng·mL^-1）	MMP-9/ （ng·mL^-1）
组别		PANSS阳性症状评分/分		PANSS阴性症状评分/分	PANS一般精神病理评分/分	是/例	否/例	NRG-1/ （ng·mL^-1）	MMP-9/ （ng·mL^-1）
认知正常组		12.42±5.66		22.43±7.30	27.83±7.42	22	20	5.86±0.88	470.79±157.15
认知障碍组		14.65±6.14		20.86±6.40	28.46±7.37	45	17	4.80±0.65	587.10±137.88
统计值		1.332		1.511	0.926	4.457		7.062	3.990
P值		0.190		0.134	0.357	0.035		<0.001	<0.001

项目	β值	标准误	Wald值	OR值（95%CI）	P值
性别（男=0，女=1）	0.990	0.590	2.816	2.690（0.847~8.546）	0.093
抗乙酰胆碱药物（使用=0，未使用=1）	-1.832	0.678	7.301	0.160（0.042~0.605）	0.007
NRG-1	-1.952	0.441	19.614	0. 142（0.060~0.337）	<0.001
MMP-9	0.006	0.002	6.260	1.006（1.001~1.011）	<0.001